From largest biotech IPO of the past few years to this endpts.com/acelyrin-sheds…

every time i return home from a mini vacation, my first thought is: i should just quit my job, right?

Gilead’s $4.3 billion acquisition of CymaBay earlier this year is shaping up: the FDA has approved the biotech’s primary biliary cholangitis drug seladelpar, to be marketed as Livdelzi accessdata.fda.gov/drugsatfda_doc… Gilead bid against itself for the drugmaker endpts.com/gilead-bid-aga…

BREAKING: Mpox is now a global emergency, the World Health Organization says, with cases in 13 countries and a new form of the virus spreading. apnews.com/article/who-mp…

Biden administration says IRA negotiations will result in $6B in 2026 Medicare savings - and $1.5B in OOP savings. Both those savings numbers are reflective of the net (not list) prices but HHS says they don’t plan to release the indiv. net prices endpts.com/biden-administ…

The first 10 drug price negotiations under the IRA are here: endpts.com/federal-govern…

Mpox antiviral tecovirimat didn't show benefit in a randomized, NIH trial in the DRC (Clade 1, which has caused more severe disease). Very disappointing news given yesterday's WHO declaration. Antivirals for acute infections are hard.... nih.gov/news-events/ne…

six days after FDA rejected its MDMA-assisted PTSD therapy, Lykos Therapeutics says it’s laying off 75% of its staff longtime psychedelics advocate Rick Doblin is departing board & adding ex-leader of depression drug Spravato, J&J’s esketamine nasal spray, as medical advisor

I tried to leave no stone unturned after a difficult day for Lykos and the employees there. Our Endpoints News interview with CEO Amy Emerson on what, exactly, is next: endpts.com/qa-lykos-just-…

"There’s actually a lot of leverage and control that the MAPS board has on Lykos." Meghana Keshavan with the first interview with Rick Doblin and its packed with details. statnews.com/2024/08/17/mdm…

Late-stage autoimmune biotech Zenas BioPharma reveals IPO pitch as $ZBIO Boston-area biotech confidentially filed in January, then disclosed a $200 million Series C in May It’s in Phase 3 and multiple Phase 2 trials w/ex-Xencor antibody endpts.com/autoimmune-bio…

3 yrs ago, the Biden Administration announced a $3.2B plan to build antivirals for Covid and whatever pandemic nature might throw at us next Most of the plan, I learned, was never enacted. And what was built — 9 antiviral centers — may soon be dismantled statnews.com/2024/08/26/nih…

We're heartbroken the great Amber Tong is leaving us, but excited to keep reading her byline❤️ And... WE'RE HIRING! They're big shoes to fill, but we are on the hunt for a senior journalist to join our amazing team in London. Applications are open! ats.rippling.com/endpointsnews/…

Every weekday morning starts with wisdom and guidance from Amber. Gonna miss having her as a coworker. She’s helped drive Endpoints News for many years and makes our virtual newsroom buzz

CTA boss Dorval Carter spent more time traveling the world than visiting Chicago transit stations, his schedule shows. ✍️ Manny Ramos reports: buff.ly/3ABtm2E